AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10422491
Drug: no hypolipemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no hypolipemic medication
Trial: 7999482
Drug: Continuous i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous i.v. infusion (group A: 1.25 u.h‐1)
Trial: 2897785
Drug: Somatostatin (SRIF)
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin (SRIF) infusion (500 micrograms/h) for 90 min before and 5 h after a protein meal (240 g of meat)
Trial: 21059836
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (5 g/d)
Trial: 21059836
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (10 g/d)
Trial: 21059836
Drug: rhGH (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (3 μg/kg/d)
Trial: 21059836
Drug: rhGH (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (5 μg/kg/d)
Trial: 21059836
Drug: Co-treatment with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-treatment with rhGH
Trial: 21059836
Drug: Changes in
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in testosterone and insulin‐like growth factor 1 levels
Trial: 14669258
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa oil (black seed oil) at a dose of 40 to 80 mg/kg/day
Trial: 9085939
Drug: Plasma IL-1
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasma IL-1 receptor antagonist and IL-10 levels
Trial: 1493941
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no GM-CSF treatment)
Trial: 27890522
Drug: Tamsulosin (alpha-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (alpha-adrenergic blocker)
Trial: 17264337
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 6) and Paclitaxel (200 mg/m2 every 3 weeks)
Trial: 17264337
Drug: Gemcitabine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1 g/m2 days 1 and 8) and Cisplatin (60 mg/m2 day 1 every 3 weeks)
Trial: 12933419
Drug: IT fentanyl
RxNorm normalized name: IT-139
DrugBank: IT-139 (DB17145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT fentanyl 25 micro g and hyperbaric bupivacaine 2.5 mg (Group H)
Trial: 12933419
Drug: IT fentanyl
RxNorm normalized name: IT-139
DrugBank: IT-139 (DB17145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT fentanyl 25 micro g and plain bupivacaine 2.5 mg (Group P)
Trial: 10407502
Drug: LDL-apheresis and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-apheresis and drugs
Trial: 1810257
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (1000 mg orally)
Trial: 29024278
Drug: Loop diuretic
RxNorm normalized name: Loop diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop diuretic bumetanide
Trial: 15680453
Drug: Initial conservative
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial conservative treatment (medical treatment, with later evacuation allowed if necessary)
Trial: 12922086
Drug: New pediatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New pediatric tick-borne encephalitis (TBE) vaccine
Trial: 10669065
Drug: Daily combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily combination tablet administration (8 mg buprenorphine + 2 mg naloxone)
Trial: 10669065
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg alternate-day buprenorphine administration
Trial: 10669065
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg alternate-day buprenorphine administration
Trial: 10669065
Drug: Placebo on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo on interposed day during alternate-day treatment
Trial: 8797613
Drug: Low-dose anti-tumor
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose anti-tumor necrosis factor therapy
Trial: 8797613
Drug: High-dose anti-tumor
RxNorm normalized name: G 1 (anti-tumor agent)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose anti-tumor necrosis factor therapy
Trial: 1632683
Drug: Single donor-specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single donor-specific transfusion (DST) 24 to 48 hours before transplant with intravenous cyclosporine initiated after transfusion
Trial: 6208968
Drug: Banked breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Banked breast milk or maternal milk supplement
Trial: 30641007
Drug: Xinfeng Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinfeng Capsule (XFC), 0.5 g per pill, 3 pills each time, three times per day for 12 weeks
Trial: 30641007
Drug: Sulfasalazine (SASP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (SASP), 0.25 g per tablet, 4 tablets each time, twice per day for 12 weeks
Trial: 22124360
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (1110 MBq)
Trial: 20556834
Drug: Colchicine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1 mg/d)
Trial: 6753887
Drug: Oral disopyramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral disopyramide phosphate (loading dose 150, 200, or 300 mg followed by 100, 150, or 200 mg every 6 hours based on weight)
Trial: 25858261
Drug: Doxycycline (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (oral, twice daily for 7 days)
Trial: 21142946
Drug: Soymilk (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soymilk (500 mL daily for 21 days)
Trial: 19172254
Drug: Allicin (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allicin (180 mg capsule once daily for 14 days)
Trial: 16728906
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oral risperidone and 2 mg IM lorazepam
Trial: 16728906
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral haloperidol and 2 mg IM lorazepam
Trial: 16728906
Drug: oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo and 2 mg IM lorazepam
Trial: 11334901
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 17‐beta
Trial: 8322566
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg methadone
Trial: 8322566
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg diamorphine
Trial: 30883839
Drug: Cladribine tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine tablets 5.25 mg/kg
Trial: 28140753
Drug: Cladribine tablets
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cladribine tablets (both dosages)
Trial: 26402703
Drug: BoNT‐A injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT‐A injection of 50 U
Trial: 26402703
Drug: BoNT‐A injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT‐A injection of 100 U
Trial: 26402703
Drug: BoNT‐A injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BoNT‐A injection of 200 U
Trial: 14970982
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi (alone or in combination with other therapies)
Trial: 11694607
Drug: Full-strength tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-strength tea (15 g)
Trial: 11694607
Drug: Caffeinated water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated water (270 mg caffeine)
Trial: 11694607
Drug: Half-strength tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-strength tea (7.5 g)
Trial: 856049
Drug: Betamethasone 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone 0.1% as valerate in an ointment base
Trial: 27816035
Drug: Four sessions
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four sessions of smoking cessation counseling plus 12 weeks of bupropion treatment and brief physician advice to quit
Trial: 27816035
Drug: No counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No counseling plus 12 weeks of bupropion treatment and brief physician advice to quit
Trial: 25378648
Drug: Docetaxel 20
RxNorm normalized name: docetaxel 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 20 mg/m² plus cisplatin 25 mg/m² on Day 1, 8, and 15 (docetaxel plus cisplatin)
Trial: 25378648
Drug: Docetaxel 25
RxNorm normalized name: docetaxel 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 25 mg/m² on the same schedule (docetaxel)
Trial: 17317857
Drug: High-dose imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose imatinib (800 mg)
Trial: 23572137
Drug: High-dose imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose imatinib (800 mg) in combination with intermediate-dose cytarabine (200 mg/m2 for 7 days)
Trial: 16616232
Drug: Lipo-ecraprost (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipo-ecraprost (60 microg, administered intravenously on each of 5 days per week for 8 weeks)
Trial: 7962654
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose cyclosporin plus nifedipine
Trial: 7962654
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose cyclosporin
Trial: 7962654
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cyclosporin plus azathioprine
Trial: 3296733
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg i.v. bolus, then 20 mg/h by infusion for 4 h (low-dose continuous infusion metoclopramide)
Trial: 3296733
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg i.v. bolus every 2 h for three doses (high-dose bolus metoclopramide)
Trial: 29020355
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 or 25 mg once daily
Trial: 20594207
Drug: Community Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community Control (CC)
Trial: 19064521
Drug: B vitamin
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamin supplementation (2.5 mg folic acid/d, 50 mg vitamin B‐6/d, and 1 mg vitamin B‐12/d)
Trial: 8645503
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg eugenol for 7 days
Trial: 7515704
Drug: High-dose thrombin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose thrombin time (HITT)
Trial: 3606928
Drug: 5000 units
RxNorm normalized name: A-25, 25000 units oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 units heparin
Trial: 31991063
Drug: Decongesting therapy
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decongesting therapy guided by ultrasound assessment of the IVC in addition to clinical assessment
Trial: 29331711
Drug: Omega-3 supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplements (638mg DHA and 772mg EPA per day)
Trial: 27474214
Drug: Control group;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group; evidence-based dietetic advice with 6 monthly nurse follow-up
Trial: 24717368
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of 12 oz (355 mL)/d SSB (equivalent to 1 can of soda per day)
Trial: 18464224
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid and long acting‐b‐agonists (LABA) combination therapy
Trial: 18464224
Drug: Long-term combined
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term combined therapy with inhaled corticosteroid and LABA
Trial: 18464224
Drug: Combination inhalers
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination inhalers (LABA and CS)
Trial: 17059771
Drug: GEL (4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEL (4% succinylated gelatin)
Trial: 17059771
Drug: RL (lactated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RL (lactated Ringer's solution)
Trial: 8841214
Drug: Endocervical 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocervical 0.5 mg of PGE2 gel
Trial: 1517923
Drug: Intravenous immune
RxNorm normalized name: Intravenous immune globulin (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immune globulin (IVIG) therapy (500 mg/kg)
Trial: 1517923
Drug: Albumin treatment
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin treatment (5 mg/kg)
Trial: 30700116
Drug: Short-TXA (three-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-TXA (three-hour two-dose regimen)
Trial: 30700116
Drug: Long-TXA (11-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-TXA (11-hour four-dose regimen)
Trial: 17463460
Drug: Drug intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug intervention to prevent diabetes (specific drug not mentioned)
Trial: 15045169
Drug: Systematic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systematic administration of the Bloomsbury Sedation Score and the Glasgow Coma Scale
Trial: 15045169
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of sedative drugs during weaning, timely extubation, increased surveillance
Trial: 12194393
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml 0.5 mg neostigmine
Trial: 12194393
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml normal saline
Trial: 8602376
Drug: zidovudine 600
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zidovudine 600 mg/day alone
Trial: 8602376
Drug: zidovudine with
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zidovudine with cimetidine 1200 mg/day
Trial: 8602376
Drug: zidovudine with
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zidovudine with ranitidine 300 mg/day
Trial: 319269
Drug: Ephedrine sulfate
RxNorm normalized name: Ephedrine Sulfate
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine sulfate and theophylline combination
Trial: 31325161
Drug: Subcutaneous somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous somatostatin (22 µg/kg)
Trial: 31325161
Drug: Intravenous somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous somatostatin (22 µg/kg)
Trial: 27873023
Drug: Acetylcysteine (AC)
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylcysteine (AC) 3 × 100 mg for 3 weeks
Trial: 27873023
Drug: Azithromycin (AZ)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (AZ) body weight adjusted dose for 3 days
Trial: 27873023
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Acetylcysteine and Azithromycin at described doses
Trial: 18071727
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (prednisone, aspirin, progesterone)
Trial: 18071727
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment vs Enoxaparin
Trial: 18071727
Drug: Treated groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treated groups (Enoxaparin and Combination)
Trial: 9075507
Drug: Lignocaine 300
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 300 mg alone
Trial: 9075507
Drug: Lignocaine 300
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 300 mg with fentanyl 100 micrograms
Trial: 9075507
Drug: Lignocaine 200
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 200 mg with fentanyl 100 micrograms
Trial: 7924831
Drug: Antioxidants (cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidants (cocktail of several antioxidants at high dosage)
Trial: 7924831
Drug: Lymphocyte photopheresis
RxNorm normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphocyte photopheresis (treatment of lymphocytes with methoxypsoralen and UVA irradiation)
Trial: 3555054
Drug: Ciprofloxacin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (750 mg twice daily for seven days)
Trial: 3555054
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg twice daily for seven days)
Trial: 28189366
Drug: ECP002A (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECP002A (oral formulation of Δ9-tetrahydrocannabinol)
Trial: 27942550
Drug: Palifermin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palifermin (60 μg/kg/day as an intravenous bolus once daily for 3 days before and 3 days after chemotherapy)
Trial: 27942550
Drug: Chlorhexidine mouthwash
RxNorm normalized name: chlorhexidine Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine mouthwash (once daily for 3 days before and 3 days after chemotherapy)
Trial: 24148140
Drug: Interventions designed
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interventions designed to link those with SUDs to treatment
Trial: 20233982
Drug: Pharmacist-assisted medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-assisted medication reconciliation, inpatient pharmacist counseling, low-literacy adherence aids, and tailored telephone follow-up after discharge
Trial: 18397986
Drug: Sulfonylurea (SU)
RxNorm normalized name: sulfanilylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea (SU) treatment
Trial: 11004361
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus amnioinfusion (500 mL over 30 minutes, repeated if necessary)
Trial: 11004361
Drug: Continuous amnioinfusion
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous amnioinfusion (500 mL over 30 minutes, then 3 mL per minute until delivery)
Trial: 1350596
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS and beta-blocker combination
Trial: 6364879
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg oral administration)
Trial: 30016193
Drug: Pulsed Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Nd:YAG laser (high-intensity laser therapy) with exercise program, 600 J in two phases and 15 J to 10 points for a total of 750 J for each knee, thrice per week for 4 weeks.
Trial: 30016193
Drug: Pulsed Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Nd:YAG laser (high-intensity laser therapy) with exercise program, thrice per week for 4 weeks.
Trial: 27959716
Drug: Celecoxib (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (mean daily dose: 209±37 mg)
Trial: 27959716
Drug: Naproxen (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (mean daily dose: 852±103 mg)
Trial: 27959716
Drug: Ibuprofen (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (mean daily dose: 2045±246 mg)
Trial: 27959716
Drug: Celecoxib (on-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (on-treatment analysis)
Trial: 27959716
Drug: Naproxen (on-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (on-treatment analysis)
Trial: 27959716
Drug: Ibuprofen (on-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (on-treatment analysis)
Trial: 24343476
Drug: Aripiprazole (3.22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (3.22 mg/day)